Dr. Reddy's Laboratories Ltd Common Stock vs 22nd Century Group Inc — how do they compare? Dr. Reddy's Laboratories Ltd Common Stock trades at $12.75 (market cap $10.78B), while 22nd Century Group Inc trades at $0.65 (market cap $475.95K). The key difference: Dr. Reddy's Laboratories Ltd Common Stock is far larger — about 22649.4× 22nd Century Group Inc's market cap, and Dr. Reddy's Laboratories Ltd Common Stock pays a 0.65% dividend while 22nd Century Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dr. Reddy's Laboratories Ltd Common Stock for 0 Days and 22nd Century Group Inc for 33 Days on average.
| RDY | XXII | |
|---|---|---|
Market Cap | $10.78B | $475.95K |
Volume | 2,724,343 | 78,911 |
Sector | Health | Consumer Staples |
52-Week High | $15.38 | $483.00 |
52-Week Low | $11.38 | $0.65 |
Typical Hold Time | 0 Days | 33 Days |
Enterprise Value | $10.68B | -$3.83M |
Dividend Yield | 0.65% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
XXII trades at $0.67, down 7.98% in the last session, with a bearish technical signal from moving averages. The company shows negative profitability metrics including -76.01% net income margin and -284.5% ROE, though valuation ratios appear low with P/S of 0.06 and P/B of 0.03. Recent news highlights regulatory progress in nicotine reduction initiatives in France and Europe.
Despite analyst optimism (75% buy ratings with $1,240 price target), fundamental challenges persist with consecutive earnings misses and negative cash flow from operations. The stock faces significant execution risk in commercializing reduced-nicotine tobacco products while navigating regulatory timelines.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Dr. Reddy's Laboratories Ltd. develops and manufactures generic medicines, active pharmaceutical ingredients (APIs), biosimilars, and over-the-counter (OTC) products, headquartered in Hyderabad, India, with therapeutic focus areas spanning gastrointestinal, cardiovascular, oncology, and dermatology.
Read more on RDY →22nd Century Group is a plant biotechnology company that uses genetic engineering and gene editing to control the levels of nicotine in tobacco plants. Its flagship product line, VLN®, is the first and only combustible cigarette authorized by the FDA as a Modified Risk Tobacco Product (MRTP), containing 95% less nicotine than traditional cigarettes to help adult smokers smoke less.
Read more on XXII →